Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is an exploratory genomic analysis of publicly available data identifying potential molecular subsets of pancreatic NETs, raising questions about prognostic stratification but lacking validation, clinical outcomes, or therapeutic testing.
Early-phase preclinical study in a murine xenograft model demonstrating proof-of-concept for a novel radiotherapeutic agent with two dosing schedules; results are encouraging but lack human translation, long-term follow-up, and mechanistic detail needed to guide clinical design.
A single case report with clinical follow-up data; no control group, no outcome quantification beyond descriptive narrative, and no generalizable evidence for efficacy.
Single-centre observational study of biomarker expression in xenograft models without clinical outcome validation; establishes feasibility and correlation patterns but lacks prospective clinical evidence or intervention trial.
Proteogenomic characterization study identifying molecular subtypes and proposing IL-33 as a therapeutic target, with preclinical validation in animal models but no clinical efficacy data in patients.
A mechanistically rigorous preclinical study demonstrating that menin inhibition reduces high-fat diet-induced weight gain in mice through intestinal lipid absorption limitation, supported by organoid validation but lacking human efficacy data.
Retrospective single-center cohort study confirming efficacy and safety outcomes of atezolizumab plus chemotherapy in advanced SCLC, replicating key endpoints from the pivotal IMpower133 trial in a real-world population.